|
| Press Releases |
|
 |
|
| Friday, September 23, 2022 |
|
|
Malaysian Genomics Grows Presence in Thailand |
| Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to announce today a series of collaborations to grow its customer base in Thailand as well as exploring opportunities for research and development (R&D) of new products and services. more info >> |
|
| Wednesday, September 21, 2022 |
|
|
Malaysian Genomics, Rinani Genotec Sign LOI with Universiti Malaysia Sabah |
| Leading genomics and biopharmaceutical specialist Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155) is pleased to report that the Group has signed a letter of intent (LOI) with the Faculty of Science and Natural Resources, Universiti Malaysia Sabah (UMS) and Rinani Genotec Sdn Bhd (Genotec) to collaborate on research and development (R&D) in genetics, and regenerative and alternative medicines. more info >> |
|
| Tuesday, August 30, 2022 |
|
|
Malaysian Genomics Reports RM28.36 Million Full-Year Revenue |
| Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, reported revenue of RM6.33 million for the fourth quarter ended 30 June 2022 (4Q 2022) compared with the loss of RM0.07 million in the corresponding quarter of the previous financial year (4Q 2021) on higher contribution from the biopharmaceutical business and continued organic growth of the genetic testing business. more info >> |
|
| Monday, August 29, 2022 |
|
|
Malaysian Genomics Signs MoU with Ajlan to explore distribution of biopharmaceutical and genetic screening services in MENA region |
| Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, today announced that the Group has signed a Memorandum of Understanding (MoU) to explore opportunities for the distribution of biopharmaceutical and genomics products and services with Ajlan & Bros Medical Company. more info >> |
|
| Thursday, August 18, 2022 |
|
|
Malaysian Genomics Explores Strategic Partnership with MAHSA Health through MoU |
| Malaysian Genomics Resource Centre Berhad's (Bursa: MGRC, 0155) wholly-owned subsidiary, MGRC Therapeutics Sdn. Bhd. signed a memorandum of understanding (MoU) with MAHSA Health Sdn Bhd to discuss the formation of a strategic partnership promoting practice-based education, research and knowledge exchange. more info >> |
|
| Wednesday, July 20, 2022 |
|
|
UCrest Partners with Malaysian Genomics to Digitalize Genome Services Worldwide |
| UCrest Berhad (ACE Market: 0005) and Malaysian Genomics Resources Centre Berhad, (ACE Market: 0155) announced today that they have signed a collaborative agreement to integrate genomic testing services into digital health platform, iMedic(TM), elevating healthcare services to the next level. more info >> |
|
| Friday, July 15, 2022 |
|
|
Malaysian Genomics Appoints New Chairman |
| Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, announced today that the Company has appointed Dato' Seri Dr Chen Chaw Min as the Independent Non-Executive Chairman of the Board of Directors. more info >> |
|
| Wednesday, July 13, 2022 |
|
|
Malaysian Genomics Forms Partnership for Expansion in Saudi Arabia |
| Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, announced today that it has entered into a strategic partnership with United Doctors Hospital (UDH) for collaboration in genomics and cell therapies. more info >> |
|
| Friday, July 8, 2022 |
|
|
Malaysian Genomics Proposes Private Placement |
| Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, announced today that the Group is proposing to undertake a private placement of up to 10% of its total number of issued shares or up to 12.42 million new placement shares at an issue price to be determined for third-party investors that will be identified later. more info >> |
|
| Wednesday, July 6, 2022 |
|
|
Malaysian Genomics to Offer First-Ever Sports-Based Tests Specific to Southeast Asian Genetic Profiles |
| Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to announce that the Group's wholly-owned subsidiary, MGRC Therapeutics Sdn Bhd (MGRCT), is collaborating with Rinani Genotec Sdn Bhd (Genotec) to offer sports-based genetic tests. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Over 20 Million Shares Repurchased in Two Days, Shoucheng Holdings Sends a Strong Signal with Decisive Action
Aug 1, 2025 01:15 HKT/SGT
|
|
|
GTJAI Successfully Issued the First Publicly Offered Digital Bond of a Chinese Securities Firm
Aug 1, 2025 00:00 HKT/SGT
|
|
|
Shoucheng Buys Back 20M Shares in 2 Days, Signals Strong Bet
Jul 31, 2025 22:40 HKT/SGT
|
|
|
Champion REIT Hosts ESG-Themed Event for a Third Year, Redefining Value and Sustainable Future of Commercial Properties Through Innovation 
Jul 31, 2025 20:10 HKT/SGT
|
|
|
Scipio Capital Advisors Capital Raise puts Alternative Asset Yield Within Reach of Accredited Investors
Jul 31, 2025 19:25 HKT/SGT
|
|
|
Revenue of LEQEMBI(R) (Preliminary Basis)
Jul 31, 2025 18:27 JST
|
|
|
New Report Reveals Key Considerations For Successful Distribution Onboarding
Jul 31, 2025 16:48 HKT/SGT
|
|
|
Transfer of Sharp Mie Plant No.2 and part of the land at Mie Base
Jul 31, 2025 17:11 JST
|
|
|
TANAKA PRECIOUS METAL GROUP Announces Business Partnership with JEPLAN to Realize a Decarbonized, Circular Society
Jul 31, 2025 15:00 JST
|
|
|
DENSO Announces First Quarter Financial Results
Jul 31, 2025 11:25 JST
|
|
|
Honda Launches All-New Prelude Teaser Page Ahead of Scheduled September 2025 Market Introduction
Jul 31, 2025 11:20 JST
|
|
|
MHI Demonstrates Transport of Relief Supplies in the Event of a Disaster Using Uncrewed Aerial Vehicles Currently in Development
Jul 31, 2025 11:00 JST
|
|
|
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
Jul 31, 2025 9:30 JST
|
|
|
New Data Presented at AAIC Demonstrates Investigational LEQEMBI(R) (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease
Jul 31, 2025 9:20 JST
|
|
|
Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025
Jul 31, 2025 9:10 JST
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
